Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both ...

Many people who struggle with weight management may experience an uncontrollable, near-obsessive preoccupation with food. | ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices ...

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

As CDMOs across the industry continue to face pressure from a fluctuating biopharma business environment, AGC Biologics is ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...